Dr. Gomella Discusses Immunotherapy in Bladder Cancer

Video

In Partnership With:

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Urologists have been using immune-based agents in the urinary tract for 20 to 30 years, making the bladder a natural home for immunotherapy, says Gomella.

Newer studies are focusing on the mechanisms of immunotherapy—determining that it fights cancers. Additionally, Gomella says, newer agents are geared more toward the systemic treatment of patients with advanced bladder cancer rather than localized disease, but those agents are in the pipeline.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine